Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Short Report

Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz

Maryam Etminani-Esfahani1, Hossein Khalili25*, Sirous Jafari3, Alireza Abdollahi4 and Simin Dashti-Khavidaki2

Author Affiliations

1 Clinical Pharmacist, Department of Clinical Pharmacy, Faculty of Pharmacy, Ahvaz University of Medical Sciences, Tehran, Iran

2 Clinical Pharmacist, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

3 Iranian Research Center for HIV/AIDS, Department of Infectious Diseases, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4 Department of pathology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

5 Department of Clinical Pharmacy, Faculty of pharmacy, Tehran University of Medical Sciences, Enghelab Ave, 1417614411, P.O.Box:14155/6451, Tehran, Iran

For all author emails, please log on.

BMC Research Notes 2012, 5:204  doi:10.1186/1756-0500-5-204

Published: 26 April 2012

Abstract

Background

It was reported that antiretroviral drugs such as efavirenz can increase the catabolism of vitamin D in HIV infected individuals. We have not found any study that evaluated effects of vitamin D supplementation on the bone specific biomarkers in HIV positive patients under treatment with antiretroviral regimen containing efavirenz.

Findings

Vitamin D deficiency was detected in 88.4 % of included patients. Baseline osteocalcin, but not collagen telopeptidase, serum levels were lower than normal range in all of these individuals. Both bone biomarkers’ concentrations increased significantly (p < 0.001 for both of them) after supplementation of vitamin D and it was more predominant for osteocalcin.

Conclusion

In the HIV-infected patients under treatment with efavirenz, vitamin D deficiency is prevalent. After supplementation with single dose of 300,000 IU vitamin D in this population, the activation of osteoblasts and osteoclasts stimulates bone formation and resorption respectively with favorable bone formation without any adverse event. Significant percent of HIV infected individuals are vitamin d deficient that could benefit from vitamin D supplementation.

Keywords:
HIV; Efavirenz; Vitamin D